In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor.

@article{Podolin2013InVA,
  title={In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor.},
  author={Patricia L. Podolin and Brian J. Bolognese and Joseph F Foley and Edward Long and Brian Peck and Sandra T Umbrecht and Xiaojun Zhang and Penny Zhu and Benjamin Schwartz and Wensheng Xie and Chad Quinn and Hongwei Qi and Sharon Sweitzer and Stephanie Chen and Marc Galop and Yun Min Ding and Svetlana L. Belyanskaya and David I. Israel and Barry A. Morgan and David J. Behm and Joseph P Marino and Edit Kurali and Mary S. Barnette and Ruth J. Mayer and Catherine L Booth-Genthe and James F. Callahan},
  journal={Prostaglandins & other lipid mediators},
  year={2013},
  volume={104-105},
  pages={25-31}
}
Soluble epoxide hydrolase (sEH, EPHX2) metabolizes eicosanoid epoxides, including epoxyeicosatrienoic acids (EETs) to the corresponding dihydroxyeicosatrienoic acids (DHETs), and leukotoxin (LTX) to leukotoxin diol (LTX diol). EETs, endothelium-derived hyperpolarizing factors, exhibit potentially beneficial properties, including anti-inflammatory effects… CONTINUE READING